
## CONSOLIDATION: HIGH RISK ALL Page 1 of 2 

This therapy is for all patients with High Risk B-ALL or T-ALL (post-Induction)

Consolidation is 8 weeks (56 days). Begin Consolidation on Day 36 of induction or when ANC ≥ 750/µL & platelets ≥ 75,000/µL, whichever occurs later. This Therapy Delivery Map is on two (2) pages.

**VinCRIStine (VCR)**
-	Route: IV push over 1 minute
-	Dosage: 1.5 mg/m2/dose
-   Dilute with 10ml of 0.9% NaCl, IV infusion at 60ml/h
-	Used on Days 15 and 22
-	Caution: Maximum dose: 2 mg

**Intrathecal Methotrexate (IT MTX)**
-	Route: IT 
-	Dosage: 
    + Age (yrs) 1-1.99, dose 8 mg
    + Age (yrs) 2-2.99, dose 10 mg
    + Age (yrs) 3-8.99, dose 12 mg
    + Age (yrs) ≥9, dose 15 mg
    + Used on Days 1, 8, 15, 22 (Omit day 15 and day 22 for CNS3 patients)

**L-asparaginase**
-	Route: IM
-	Dosage: 6000 International Units/m2/dose (9 doses, MWF)
-	Used on: Day 15, 17, 19, Day 22, 24, 26 (MWF x 6 doses) 
-	Caution: Monitor for one hour after dose for any signs/symptoms of allergic reaction/anaphylaxis

**Cyclophosphamide (CPM)**
-	Route: IV over 30-60 min
-	Dosage: 1000 mg/m2/dose
-   Dilute with 0.9% NaCl to a target concentration of < 20 mg/mL, administer via IV infusion over 1 hour
-   If the dosage is  > 1800 mg/m 2 , the infusion should last 4 – 6 hours
-	Used on Day 1 and 29 

**Cytarabine (ARAC)**
-	Route: IV over 1-15 min or SubQ
-	Dosage: 75 mg/m2/dose
-   Dilute with 0.9% NaCl to a target concentration of < 20 mg/mL, administer via IV infusion over 1 hour
-	Used on Days 1 to 4 and 8 to 11

**Mercaptopurine (MP)**
-	Route: PO
-	Dosage: 60 mg/m2/dose 
-	Used on Days 1 to 14 
-	Caution: Dose adjust based on TPMT and NUDT15 testing. Do not give if TPMT and NUDT15 testing not done or unknown

Omit MTX IT day 15 and day 22 for CNS3 patients

CNS3 patients should receive cranial radiation at day 22 of consolidation or at the beginning of maintenance (do not do during DI) Patients with residual testicular disease should receive radiation at the beginning of consolidation Patients should have ANC ≥ 750/µL & platelets ≥ 75,000/µL to begin consolidation Day 29 therapy.
